Non Seminoma Testicular Cancer in Singapore

Non-seminoma testicular cancer is a type of germ cell tumour that develops in the testicles, the male reproductive organs responsible for producing sperm and testosterone. Unlike seminomas, non-seminomas comprise several different cell types, including embryonal carcinoma, yolk sac tumour, choriocarcinoma, and teratoma. These cancers tend to grow more rapidly than seminomas and often present at an earlier age.

Non-seminomas typically manifest as a painless lump or swelling in one testicle, though some patients may experience a dull ache or a heavy sensation in the scrotum. The cancer originates from germ cells that normally develop into sperm but undergo malignant transformation instead. These tumours can produce specific markers like alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG), which help in diagnosis and monitoring treatment response.

Treatment for non-seminoma testicular cancer involves a multi-modal approach combining surgery, chemotherapy, and sometimes additional surgical procedures depending on the cancer stage. The overall cure rate exceeds 95% when diagnosed early, and even established cases respond well to current treatment protocols. Individuals experiencing symptoms or concerns are advised to seek prompt evaluation from a testicular specialist in Singapore for accurate diagnosis and timely care.

Patients Requiring Immediate Treatment

• Males diagnosed with non-seminoma testicular cancer at any stage
• Patients with elevated tumour markers (AFP, HCG, or LDH) indicating active disease
• Those with testicular masses confirmed as non-seminoma on ultrasound and clinical examination
• Individuals with retroperitoneal lymph node involvement requiring intervention
• Patients with metastatic disease to lungs, liver, or other organs
• Young men with rapidly growing testicular masses suspicious for non-seminoma

Treatment Urgency Factors

• Size and growth rate of the primary tumour
• Presence of metastatic disease requiring prompt chemotherapy
• Tumour marker levels and their rate of increase
• Symptoms such as back pain suggesting retroperitoneal involvement
• Respiratory symptoms from lung metastases
• Risk factors including undescended testicle history or family history

Special Considerations

• Fertility preservation options before treatment initiation
• Patients with solitary testicle requiring modified surgical approach
• Those with medical conditions affecting chemotherapy tolerance
• Young patients concerned about long-term effects

Non-seminomas can progress rapidly, making prompt evaluation essential. MOH-accredited oncologists conduct thorough assessments including staging scans, tumour marker analysis, and risk stratification to determine the appropriate treatment pathway for each patient.

Radical Inguinal Orchiectomy

Radical inguinal orchiectomy remains the primary treatment for all testicular cancers. This surgical procedure involves removing the affected testicle and spermatic cord through an incision in the groin rather than the scrotum. The inguinal approach prevents potential cancer spread through scrotal lymphatics. The procedure takes approximately 45-60 minutes and can be performed under general or regional anaesthesia. Histopathological examination of the removed testicle confirms the diagnosis and identifies specific non-seminoma subtypes.

Chemotherapy Protocols

Standard chemotherapy for non-seminoma uses combination regimens based on disease stage and risk factors. The BEP regimen (bleomycin, etoposide, cisplatin) serves as the primary treatment for most patients with metastatic disease. Good-risk patients typically receive three cycles, while intermediate and poor-risk patients require four cycles. The EP regimen (etoposide, cisplatin) may be used when bleomycin is contraindicated due to lung concerns.

Retroperitoneal Lymph Node Dissection (RPLND)

RPLND may be performed as primary treatment for clinical stage I disease with high-risk features or as post-chemotherapy surgery for residual masses. The procedure involves systematic removal of lymph nodes from the retroperitoneum through either open surgery or minimally invasive techniques. Nerve-sparing modifications help preserve ejaculatory function while maintaining oncologic efficacy.

Technology & Equipment Used

Modern treatment utilises CT and PET-CT imaging for accurate staging and response assessment. Robotic-assisted laparoscopy enables minimally invasive RPLND in selected cases. Tumour marker assays provide real-time monitoring of treatment response. Pulmonary function testing guides bleomycin administration, while audiometry and renal function tests monitor cisplatin toxicity.

Pre-Treatment Preparation

Before initiating treatment, patients undergo comprehensive staging evaluation including CT scans of chest, abdomen, and pelvis. Tumour markers (AFP, HCG, LDH) are measured to establish baseline levels. Pulmonary function tests assess lung capacity before potential bleomycin therapy. Sperm banking is offered to all patients desiring future fertility, as both surgery and chemotherapy can affect sperm production. Blood tests evaluate kidney function, liver function, and blood counts. Patients receive detailed education about their treatment plan and potential side effects.

During the Procedure

For orchiectomy, patients receive anaesthesia before the surgeon makes a 5-7cm incision in the groin. The spermatic cord is clamped and divided high, and the testicle is delivered through the incision. A prosthetic implant can be placed if desired. For chemotherapy, patients receive pre-medications to prevent nausea and allergic reactions. Each cycle involves specific day protocols with intravenous infusions administered in the oncology day unit. Hydration protocols protect kidney function during cisplatin administration.

Immediate Post-Treatment

Following orchiectomy, patients recover for 1-2 hours before discharge home the same day. Ice packs reduce swelling, and pain medication manages discomfort. After chemotherapy infusions, patients are monitored for immediate reactions. Anti-emetics control nausea, and growth factor support may be given to maintain blood counts. Regular blood tests track tumour markers and organ function. Patients receive clear instructions about warning signs requiring immediate medical attention.

First 24-48 Hours

After orchiectomy, patients should rest with the scrotum elevated to reduce swelling. Pain is typically manageable with prescribed medications. Walking is encouraged to prevent blood clots, but heavy lifting is restricted. Following chemotherapy sessions, patients may experience fatigue and nausea despite preventive medications. Maintaining hydration helps flush chemotherapy drugs from the system. Temperature monitoring is crucial as chemotherapy can increase infection risk.

First Week

Surgical patients gradually increase activity while avoiding strenuous exercise. The incision is kept clean and dry, with showering permitted after 48 hours. Scrotal support provides comfort during healing. Chemotherapy patients experience peak side effects around day 7-10 of each cycle, including potential hair loss, mouth sores, and fatigue. Blood counts reach their lowest point (nadir) requiring careful infection precautions. Dietary modifications help manage taste changes and maintain nutrition.

Long-term Recovery

Complete recovery from orchiectomy takes 2-4 weeks, with return to normal activities including exercise and sexual function. Chemotherapy recovery extends 3-6 months after the final cycle for energy levels to normalise. Hair regrowth begins 1-2 months post-treatment. Long-term monitoring includes regular tumour markers, CT scans, and chest X-rays following specific surveillance protocols. Testosterone levels are monitored as some patients require hormone replacement. Fertility typically recovers 12-24 months after chemotherapy completion, though this varies individually.

Modern treatment protocols for non-seminoma testicular cancer offer good cure rates, with over 95% of patients achieving complete remission when diagnosed at early stages. Even patients with established metastatic disease have cure rates exceeding 70-80% with appropriate chemotherapy. The multi-modal treatment approach effectively eliminates both primary and metastatic disease, preventing cancer recurrence.

Radical orchiectomy provides immediate removal of the primary tumour source, rapidly reducing tumour burden and marker levels. This allows accurate pathological diagnosis to guide subsequent treatment decisions. Chemotherapy effectively treats micrometastatic disease invisible on imaging studies, while shrinking visible metastases in lymph nodes, lungs, or other organs.

For carefully selected patients, surveillance after orchiectomy avoids chemotherapy toxicity while maintaining positive outcomes through close monitoring. Post-chemotherapy surgery removes chemotherapy-resistant teratoma elements, completing the treatment pathway. Most patients return to normal work, recreational activities, and sexual function after treatment completion. Fertility preservation options and eventual recovery of sperm production allow many men to father children naturally after treatment.

Common Side Effects

During chemotherapy, most patients experience temporary hair loss affecting the scalp and body. Nausea and vomiting occur despite preventive medications but improve with each cycle. Fatigue progressively increases throughout treatment, peaking after the final cycle. Taste changes and decreased appetite affect nutritional intake. Low blood counts increase infection risk, requiring precautions during treatment. Peripheral neuropathy causes tingling in fingers and toes, usually improving after treatment completion.

Rare Complications

Bleomycin can cause lung toxicity in 3-5% of patients, requiring pulmonary monitoring and possible drug discontinuation. Cisplatin may cause permanent hearing loss at high frequencies and kidney function impairment if not properly managed. Secondary malignancies occur in less than 1% of patients many years after treatment. Retroperitoneal surgery carries risks of retrograde ejaculation affecting fertility. Cardiovascular complications including heart disease and metabolic syndrome may develop years after treatment.

Our experienced oncology team employs established protocols to minimise these risks through careful patient selection, dose modifications when necessary, and vigilant monitoring throughout treatment. Regular follow-up allows early detection and management of any late effects.

Treatment costs for non-seminoma testicular cancer vary based on disease stage and required interventions. Initial orchiectomy and staging evaluations form the baseline costs. Chemotherapy expenses depend on the number of cycles, specific drugs used, and supportive medications required. Hospital admissions for chemotherapy administration or complication management add to overall costs.

Current imaging including CT and PET scans for staging and surveillance contributes to expenses. Post-chemotherapy surgery if required involves additional surgical and hospitalisation fees. Long-term surveillance with regular imaging and blood tests continues for 5-10 years. Fertility preservation through sperm banking incurs separate charges but represents an important consideration for young patients.

The comprehensive nature of testicular cancer treatment reflects the complexity of achieving cure while minimising long-term effects. Our patient coordinators can discuss specific cost estimates during your consultation based on your individual treatment plan.